Literature DB >> 15384015

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.

Kunitoshi Iseki1, Yoshiharu Ikemiya, Taku Inoue, Chiho Iseki, Kozen Kinjo, Shuichi Takishita.   

Abstract

BACKGROUND: Uric acid may be a true mediator of renal disease and progression. However, epidemiological evidence for the significance of serum uric acid levels on the risk for developing end-stage renal disease (ESRD) is scarce in a setting of community-based screening.
METHODS: Participants in a 1993 mass screening conducted by the Okinawa General Health Maintenance Association in Okinawa, Japan, were investigated: 48,177 screenees (22,949 men, 25,228 women) older than 20 years for whom serum uric acid data were available were studied. All dialysis patients treated in Okinawa were independently registered in the Okinawa Dialysis Study registry. Participants in the 1993 screening who later entered a dialysis program were identified by using 2 computer registries. The cumulative incidence of ESRD was calculated according to quartiles of baseline serum uric acid levels for each sex. The significance of hyperuricemia (serum uric acid level > or = 7.0 mg/dL [> or =416 micromol/L] in men and > or = 6.0 mg/dL [> or =357 micromol/L] in women) for the risk for developing ESRD was evaluated by means of the Cox model after adjusting for age, blood pressure, body mass index, proteinuria, hematocrit, and total cholesterol, triglyceride, fasting blood glucose, and serum creatinine levels.
RESULTS: Mean serum uric acid level was 6.4 +/- 1.4 (SD) mg/dL (381 micromol/L) in men and 4.8 +/- 1.1 mg/dL (286 micromol/L) in women. Prevalences of hyperuricemia were 31.9% in men and 13.6% in women. By the end of 2000, a total of 103 screenees (53 men, 50 women) entered dialysis programs. Calculated incidences of ESRD per 1,000 screenees were 1.22 for men without hyperuricemia and 4.64 for men with hyperuricemia and 0.87 for women without hyperuricemia and 9.03 for women with hyperuricemia. Adjusted hazard ratios for hyperuricemia were 2.004 (95% confidence interval, 0.904 to 4.444; P = not significant) in men and 5.770 (95% confidence interval, 2.309 to 14.421; P = 0.0002) in women.
CONCLUSION: Screenees with hyperuricemia were associated with a greater incidence of ESRD. Hyperuricemia (serum uric acid > or = 6.0 mg/dL [> or =357 micromol/L]) was an independent predictor of ESRD in women. Strategies to control serum uric acid levels in the normal range may reduce the population burden of ESRD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384015

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  169 in total

1.  The relationship between serum uric acid and chronic kidney disease among Appalachian adults.

Authors:  Loretta Cain; Anoop Shankar; Alan M Ducatman; Kyle Steenland
Journal:  Nephrol Dial Transplant       Date:  2010-05-25       Impact factor: 5.992

2.  Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.

Authors:  Stacey E Jolly; Mihriye Mete; Hong Wang; Jianhui Zhu; Sven O E Ebbesson; V Saroja Voruganti; Anthony G Comuzzie; Barbara V Howard; Jason G Umans
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-01-04       Impact factor: 3.738

3.  Racial/ethnic and sex differences in the relationship between uric acid and metabolic syndrome in adolescents: an analysis of National Health and Nutrition Survey 1999-2006.

Authors:  Mark D DeBoer; Lili Dong; Matthew J Gurka
Journal:  Metabolism       Date:  2011-10-13       Impact factor: 8.694

Review 4.  End stage renal disease.

Authors:  Yoshio N Hall; Glenn M Chertow
Journal:  BMJ Clin Evid       Date:  2007-10-17

5.  Risk factors for end-stage renal disease: 25-year follow-up.

Authors:  Chi-yuan Hsu; Carlos Iribarren; Charles E McCulloch; Jeanne Darbinian; Alan S Go
Journal:  Arch Intern Med       Date:  2009-02-23

Review 6.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

Review 7.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

8.  Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population.

Authors:  H Takase; G Kimura; Y Dohi
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

9.  Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.

Authors:  Fatemeh Ghane Sharbaf; Farahnak Assadi
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

10.  Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.

Authors:  Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Neil R Johnston; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.